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Background: Morphine and fentanyl are opioid analgesics in wide clinical use that act through the μ-opioid receptor
(MOR). However, one limitation of their long-term effectiveness is the development of tolerance. Receptor
desensitization has been proposed as a putative mechanism driving tolerance to G protein-coupled receptor (GPCR)
agonists. Recent studies have found that tolerance to morphine is mediated by the c-Jun N-terminal Kinase (JNK)
signaling pathway. The goal of the present study was to test the hypotheses that: 1) JNK inhibition will be antinociceptive
on its own; 2) JNK inhibition will augment morphine antinociception and; 3) JNK mediates chronic tolerance for the
antinociceptive effects of morphine using acute (hotplate and tail-flick), inflammatory (10 μl of formalin 2.5 %) and
chemotherapy (cisplatin 5 mg/kg ip once weekly)-induced neuropathic pain assays.
Results: We found that JNK inhibition by SP600125 (3 mg/kg) produces a greater antinociceptive effect than morphine
(6 mg/kg) alone in the formalin test. Moreover, co-administration of morphine (6 mg/kg) with SP600125 (3 mg/kg)
produced a sub-additive antinociceptive effect in the formalin test. We also show that pre-treatment with SP600125 (3
or 10 mg/kg), attenuates tolerance to the antinociceptive effects of morphine (10 mg/kg), but not fentanyl (0.3 mg/kg),
in the tail-flick and hotplate tests. Pre-treatment with SP600125 also attenuates tolerance to the hypothermic effects of
both morphine and fentanyl. We also examined the role of JNK in morphine tolerance in a cisplatin-induced model of
neuropathic pain. Interestingly, treatment with SP600125 (3 mg/kg) alone attenuated mechanical and cold allodynia in
a chemotherapy-induced pain model using cisplatin. Strikingly, SP600125 (3 mg/kg) pre-treatment prolonged the
anti-allodynic effect of morphine by several days (5 and 7 days for mechanical and cold, respectively).
Conclusions: These results demonstrate that JNK signaling plays a crucial role in mediating antinociception as well as
chronic tolerance to the antinociceptive effects of morphine in acute, inflammatory, and neuropathic pain states. Thus,
inhibition of JNK signaling pathway, via SP600125, represents an efficacious pharmacological approach to delay
tolerance to the antinociceptive effects of chronic morphine in diverse pain models.
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Morphine and fentanyl are two opioid drugs commonly
used for the treatment of pain [1]. Both compounds
elicit their primary analgesic effects through activation
of the μ-opioid receptor (MOR), a member of the G
protein-coupled receptor (GPCR) superfamily. MOR is
one of the most studied members of this family due to
its relevance in pain management and dependence [2, 3].
Despite the clinical utility of MOR agonists, unwanted
side effects such as respiratory depression, dependence
and the rapid development of pharmacological tolerance
limit the long-term clinical use of these analgesics in the
outpatient setting [4].
Several mechanisms have been proposed for the devel-
opment of tolerance to the antinociceptive effects of
morphine. The desensitization of MOR signaling through
its uncoupling from cognate effector pathways has been
suggested to be a primary mechanism driving tolerance to
opioid analgesics. Multiple studies have demonstrated the
loss of MOR-effector coupling following chronic treat-
ment with agonist [4–7]. Desensitization of MOR involves
agonist-specific phosphorylation at C-terminal threonine
370 and/or serine 375 [8]. Phosphorylation at these resi-
dues is mediated primarily by GRK 2 and/or GRK 3 and
causes the recruitment of β-arrestin 2 [8, 9]. Interaction
between the phosphorylated MOR and β-arrestin 2 un-
couples MOR from its associated G proteins and is also
required for clathrin-mediated endocytosis [4, 10, 11]. In-
ternalized MOR can be trafficked to the lysosome for deg-
radation or can undergo dephosphorylation, leading to
resensitization and recycling to the plasma membrane [9,
12]. Several other possible mechanisms have been impli-
cated in the development of tolerance to opioid analgesics
including the presence of delta opioid receptors [13, 14],
glutamate signaling through NMDA receptors [15], nitric
oxide signaling [16], protein kinase C activity [17], as well
as down-regulation of MOR [4, 18].
Recent studies have demonstrated that JNK is involved
in regulation of MOR signaling and tolerance for some
opioid agonists. SP600125 is an anthrapyrazolone com-
pound that inhibits JNK1, JNK2, and JNK3 with similar
high affinity (Ki = 0.19 μM) [19]. Further, SP600125 ex-
hibits >20 fold selectivity for JNKs compared to other
MAPK pathway family members and also >100 fold select-
ivity relative to more distantly related kinases such as pro-
tein kinases A and C. SP600125 exhibits efficacy in cells
(where it dose dependently inhibits c-Jun phosphoryl-
ation) and in animals (where it can block lipopolysacchar-
ide (bacterial) induced expression of tumor necrosis
factor-alpha) [19]. Recently, pre-treatment with SP600125,
has been shown to block acute tolerance to the antinoci-
ceptive effects of morphine, morphine-6-glucoronide, and
buprenorphine in mice [20]. Conversely, acute tolerance
to fentanyl-induced antinociception was not affected byinhibition of JNK signaling, but was absent in GRK3
knock-out (KO) mice [20]. These data demonstrate func-
tional selectivity in opioid tolerance mechanisms differen-
tially involving JNK and GRK signaling mechanisms [20].
Chronic SP600125 treatment prevents the development of
chronic tolerance to antinociceptive [15, 21], as well as
antiallodynic effects of morphine in a sciatic nerve injury
model of neuropathic pain [22].
The present study utilized different pain models to
evaluate the role of JNK signaling in the development of
morphine tolerance in mice. First, we tested the hypoth-
esis that SP600125 treatment alone elicits dose-dependent
antinociception in the formalin test, an animal model
of inflammatory pain. Second, we examined whether
SP600125 treatment enhances morphine antinocicep-
tion in the formalin test. Third, we determined the
contribution of JNK signaling to the development of
antinociceptive tolerance to both morphine and fen-
tanyl in acute pain models (tail-flick and hotplate) and
examined JNK’s role in tolerance to the hypothermic ef-
fects of morphine and fentanyl. Fourth, we determined
whether JNK signaling enhances antinociception and me-
diates tolerance to the anti-allodynic effects of chronic
morphine in a model of chemotherapy-induced neur-
opathy. Together, the results of this study show that JNK
signaling causes analgesia and prevents tolerance to
chronic morphine in both nociceptive and neuropathic
pain models. Our findings demonstrate that targeting the
JNK pathway represents a novel approach for enhancing
antinociception and prevents behavioral tolerance for cer-
tain opioid analgesics such as morphine.Results
Antinociceptive effect of SP600125 in the formalin test
All four doses of SP600125 (F4,21 = 40.93, p < 0.0001), ad-
ministered systemically (i.p.), suppressed composite pain
scores relative to the vehicle-treated group in a time-
dependent manner (F44,231 = 3.49, p < 0.0001) (Fig. 1a).
This suppression was observed at 5 min (acute phase 1)
and from 30 to 40 min (inflammatory phase 2) post-
formalin injection (p < 0.0001). Composite pain scores
were also lower for the SP600125 3 mg/kg dose relative
to 0.1 mg/kg dose from 35 to 40 min post-formalin in-
jection (p < 0.017), suggesting that 3 mg/kg SP600125
produces greater antinociception (Fig. 1a). Analysis of
the Area Under the Curve (AUC) of pain behavior re-
vealed that all doses of SP600125 produced antinocicep-
tion relative to vehicle in both Phase 1 (F4,21 = 20.53, p <
0.0001) and Phase 2 (F4,21 = 42.23, p < 0.0001) of the for-
malin test (Fig. 1b and c). In the first phase, a higher
dose of SP600125 (3 mg/kg) produced a greater antino-
ciceptive effect relative to the lowest dose (0.1 mg/kg)
(p < 0.039). In the second phase, SP600125 at 3 mg/kg
Fig. 1 Antinociceptive effect of SP600125 in the formalin test.
SP600125 suppresses formalin-induced pain behavior (a) in a dose-
dependent manner. The four different doses of SP600125 (0.1, 1, 3
and 10 mg/kg) decrease the area under the curve (AUC) of (b) Phase
1 and (c) Phase 2 pain behavior. Data are expressed as mean ± S.E.M.
(n = 5–6 per group). *p < 0.0001 for SP600125 different doses vs.
vehicle group (ANOVA); + p < 0.017 vs. SP600125 (0.1 mg/kg) group
(ANOVA, Bonferroni post hoc); x p < 0.0001 vs. vehicle group
(ANOVA); #p < 0.039 for SP600125 (3 mg/kg) vs. SP600125 (0.1 mg/kg)
(ANOVA, Bonferroni post hoc); ^p < 0.048 for SP600125 (3 mg/kg) vs.
SP600125 (0.1, 1 or 10 mg/kg) (ANOVA, Bonferroni post hoc)
Fig. 2 Antinociceptive effects of morphine, SP600125 and their
combination in the formalin test. Sub-additive antinociceptive effects
of the combination of SP600125 (3 mg/kg i.p.) with morphine
(6 mg/kg i.p.) is observed for (a) the composite pain score and area
under the curve (AUC) of (b) Phase 1 and (c) Phase 2 pain behavior.
Data are expressed as mean ± S.E.M. (n = 5–6 per group). *p < 0.0001
for SP600125 different doses vs. vehicle group (ANOVA, Bonferroni
post hoc); + p < 0.021 vs. SP600125 group (ANOVA, Bonferroni post
hoc); ^p < 0.039 morphine group vs. SP600125 (3 mg/kg) group
(ANOVA, Bonferroni post hoc); x p < 0.0001 vs. vehicle group
(ANOVA); #p < 0.044 vs. SP600125 (3 mg/kg) or morphine (6 mg/kg)
(ANOVA, Bonferroni post hoc)
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other doses (p < 0.048).
Antinociceptive effects of morphine, SP600125 and their
combination in the formalin test
Systemic administration of morphine (6 mg/kg), SP600125
(3 mg/kg), and their combination suppressed composite
pain scores relative to the vehicle group (F3,19 = 215.15,
p < 0.0001) in a time-dependent manner (F33,209 = 23.09,
p < 0.0001; Fig. 2a). This suppression was observed at
5 min (acute phase 1) and from 25 to 45 min (inflamma-
tory phase 2) post-formalin injection (p < 0.0001). The
combination of morphine with SP600125 further re-
duced composite pain scores relative to treatment withSP600125 alone (p < 0.021 at 5 and 25–35 min post-
formalin). Moreover, at 5 min post-formalin, morphine
produced a greater suppression of the composite pain
score than with SP600125 alone (p < 0.039). Analysis of
the AUC of pain behavior revealed that morphine,
SP600125 and their combination reduced pain behavior
relative to the vehicle group for both phases (F3,19 =
72.33, p < 0.0001 (phase 1); F3,19 = 182.91, p < 0.0001
(phase 2)) of the formalin test (Fig. 2b and c). Moreover,
the combination of morphine with SP600125 produced
a greater antinociceptive effect than either drug given
alone for the first (p < 0.044) and second (p < 0.002)
phases, thereby revealing a sub-additive antinociceptive
Fig. 3 SP600125 delays tolerance for the antinociceptive effects of chronically administered morphine. Chronic tolerance to the antinociceptive
effects of morphine is mediated by JNK signaling. Wild-type mice were treated with vehicle (black line with triangles), 3 mg/kg SP600125 (SP6;
dashed black line with diamonds), or 10 mg/kg SP600125 (SP6; black line with diamonds) 60 min prior to administration of 10 mg/kg morphine
for ten consecutive days. Treatment with either 3 mg/kg or 10 mg/kg SP600125 delayed tolerance to the effects of chronically administered
morphine in the tail-flick test and the hot plate test. Treatment with either 3 mg/kg or 10 mg/kg SP600125 also reduced tolerance for the
hypothermic effects of chronically administered morphine. Tail-flick antinociception (a), hotplate antinociception (b), and body temperature
(c) were measured 60 min later. Acute treatment with SP600125 alone (3 mg/kg or 10 mg/kg) had no effect on tail-flick antinociception (p = 0.79),
hotplate antinociception (p = 0.36), or hypothermia (p = 0.5) (d). Data are expressed as mean ± S.E.M. (n = 9–19 per group). *p < 0.007 for SP600125
(3 or 10 mg/kg) vs. vehicle group (ANOVA, Bonferroni post hoc); + p < 0.003 for SP600125 (3 or 10 mg/kg) vs. vehicle group (ANOVA, Bonferroni
post hoc); #p < 0.016 for SP600125 (3 or 10 mg/kg) vs. vehicle group (ANOVA, Bonferroni post hoc)
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(Fig. 2b and c).
SP600125 blocks tolerance to morphine antinociception
Daily (i.p.) treatment with morphine alone resulted in
the rapid development of tolerance to the antinocicep-
tive and hypothermic effects of this drug (Fig. 3). Daily
pretreatments with the SP600125 (3 mg/kg or 10 mg/kg)
in combination with morphine prolonged tail-flick laten-
cies relative to morphine alone (F2, 40 = 22.81, p < 0.0001;
Fig. 3a) in a time-dependent manner (F20, 400 = 1.89, p <
0.012). Indeed, pre-treatment (i.p.) with SP600125 (3 mg/
kg and 10 mg/kg) blunted the antinociceptive tolerance to
morphine relative to the vehicle pre-treated group in the
tail-flick test from day 3 (F2, 52 = 5.43, p < 0.007) to day 10
(F2, 51 = 12.73, p < 0.0001) and also on day 24 (F2, 40 = 4.56,
p < 0.016). Moreover, daily pretreatment with SP600125
slowed the development of antinociceptive tolerance to
morphine in the hotplate test (F2, 24 = 14.82, p < 0.0001;
Fig. 3b). Both doses (3 mg/kg, p < 0.003 and 10 mg/kg,
p < 0.0001) of SP600125 attenuated, but did not prevent,
antinociceptive tolerance to morphine relative to vehicle-
treated group in the hotplate test. Acute treatment with
SP600125 alone (10 mg/kg n = 32) had no effect relative
to the vehicle treated group (n = 20) on tail-flick antinoci-
ception (p = 0.79), hotplate antinociception (p = 0.36), or
hypothermia (p = 0.5) (Fig. 3d).
SP600125 delays tolerance to the hypothermic effects
of morphine
Both 3 and 10 mg/kg (i.p.) of SP600125 (F2, 33 = 5.06; p =
0.012) delayed tolerance to the hypothermic effects of
chronically administered 10 mg/kg morphine in a time
dependent manner (F20, 330 = 5.59, p < 0.0001) (Fig. 3c).
Pre-treatment with either dose of SP600125 (3 mg/kg and
10 mg/kg) blunted tolerance to the hypothermic effects of
morphine compared to morphine-treated mice receiving
vehicle pre-treatment at day 6 (F2, 48 = 4.14, p < 0.022) and
day 10 (F2, 47 = 4.51, p < 0.016) (Fig. 3c).
JNK inhibition does not affect antinociceptive tolerance
to fentanyl
Chronic daily (i.p.) pretreatment with the JNK inhibitor
SP600125 (3 mg/kg or 10 mg/kg) did not attenuate de-
velopment of tolerance to the antinociceptive effects of
0.3 mg/kg fentanyl in the tail-flick test (F2, 63 = 2.41; p =
0.098; Fig. 4a) or the hotplate test (F2, 45 = 1.091; p =
0.344; Fig. 4b) at any time point (F20, 630 = 0.89; p = 0.607
for the tail-flick; F20, 450 = 0.41; p = 0.99 for the hotplate).
By contrast, pre-treatment with SP600125 (F2, 15 =
18.93; p < 0.0001) did delay tolerance to the hypothermic
effects of chronically administered 0.3 mg/kg fentanyl
(Fig. 4c). Tolerance to the hypothermic effects of fentanyl
was attenuated only by SP600125 3 mg/kg (p < 0.0001),but not by SP600125 10 mg/kg (p = 0.278) relative to
fentanyl-treated rats receiving vehicle in lieu of SP600125
(Fig. 4c).
Assessment of cisplatin-induced mechanical allodynia
following administration of SP600125, morphine, and
their combination
Cisplatin decreased mechanical paw withdrawal thresh-
olds relative to saline-treatment in mice (F1,28 = 2666.98,
p < 0.0001), consistent with the development of mechan-
ical allodynia (Fig. 5a). Mechanical allodynia was detect-
able in the absence of SP600125 or morphine-treatment
throughout the duration of this experiment from day 8
to day 25 (p < 0.0001) (Fig. 5a).
Prior to SP600125 and/or morphine treatment, base-
line measurements of cisplatin-induced mechanical allo-
dynia did not differ in any group (F3,18 = 1.03, P = 0.405)
at any time point (F54,324 = 0.81, p = 0.822) (Fig. 5b).
Mechanical paw withdrawal thresholds assessed prior to
drug injection were similar in groups of mice receiving
vehicle, morphine (6 mg/kg), SP600125 (3 mg/kg) or
morphine (6 mg/kg) combined with SP600125 (3 mg/kg)
from day 8 (F3,18 = 0.93, p = 0.447) to day 25 (F3,18 = 1.88,
p = 0.169; Fig. 5b).
Morphine (6 mg/kg; given from day 11 to day 25),
SP600125 (3 mg/kg; given from day 8 to day 25), or their
combination (SP600125 from day 8 to day 25 +mor-
phine from day 11 to day 25) were chronically adminis-
tered and tested for their anti-allodynic effects in
cisplatin-induced neuropathic pain (Fig. 5c). Morphine
(6 mg/kg), SP600125 (3 mg/kg), and their combination
all suppressed cisplatin-induced mechanical allodynia
relative to vehicle (F3,18 = 143.09, p < 0.0001) (Fig. 5c).
Morphine (6 mg/kg), SP600125 (3 mg/kg), and their com-
bination produced time-dependent (F54,324 = 14.93, p <
0.0001) attenuations of mechanical allodynia relative to
pre-injection baselines. This attenuation of mechanical
allodynia was observed relative to the vehicle group from
day 8 (F3,18 = 8.61, p < 0.001) to day 20 (F3,18 = 14.05, p <
0.0001) (Fig. 5c).
Morphine treatment alone (6 mg/kg) reversed cisplatin-
induced mechanical allodynia relative to vehicle from day
11 (p < 0.0001) to day 14 (p < 0.006) (Fig. 5c). Additionally,
morphine (6 mg/kg) administered alone increased mech-
anical paw withdrawal thresholds to a greater extent than
SP600125 (3 mg/kg) administered alone from day 11 (p <
0.009) to day 13 (p < 0.011). However, the anti-allodynic
efficacy of morphine dissipated rapidly over time, con-
sistent with development of tolerance to morphine. Con-
sequently, morphine (6 mg/kg) no longer produced
antinociception starting on its fifth day of administration
(day 15). From day 15 to day 25, morphine (6 mg/kg) no
longer produced anti-allodynic effects relative to vehicle
(p > 0.851) (Fig. 5c). SP600125 (3 mg/kg) alone alleviated
Fig. 4 Tolerance to the antinociceptive effects of fentanyl is not
blocked by SP600125. JNK inhibition attenuates chronic tolerance to
the hypothermic but not the antinociceptive effects of repeated
treatment with fentanyl (0.3 mg/kg). Wild-type mice were treated
with vehicle (black line with triangles), 3 mg/kg SP600125 (dashed
black line with diamonds), or 10 mg/kg SP600125 (black line with
diamonds) 60 min prior to administration of fentanyl (0.3 mg/kg) for
ten consecutive days. Tail-flick antinociception (a), hotplate nociception
(b), and body temperature (c) were measured 60 min later. Treatment
with only SP600125 (3 mg/kg) attenuated tolerance to the
hypothermic effects of chronically administered 0.3 mg/kg fentanyl
alone. Data are expressed as mean ± S.E.M. (n = 10–24 per group).
*p < 0.0001 for SP600125 (3 mg/kg) vs. vehicle or SP600125 (10 mg/kg)
groups (ANOVA, Bonferroni post hoc)
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from day 8 (p < 0.006) to day 19 (p < 0.0001). However, by
day 19, SP600125 (3 mg/kg) no longer produced antinoci-
ception (Fig. 5c).
Morphine (6 mg/kg) combined with SP600125 (3 mg/
kg) suppressed cisplatin-induced mechanical allodynia in
comparison to the vehicle group from day 8 (p < 0.013)
until day 20 (p < 0.001). Morphine combined with SP600125
induced paw withdrawal thresholds similar in magnitude
to morphine alone on the initial day of morphine dosing
(day 11; p = 1.000) and on day 12 (p = 1.000). However,
the anti-allodynic effect of morphine combined with
SP600125 was greater than administration of morphine or
SP600125 given alone from day 13 (p < 0.001 for each
comparison) to the day 20 (P < 0.01 for each comparison),
when tolerance to morphine anti-allodynic efficacy was
developing. From day 21 to day 25, when SP600125
treatment no longer produced antinociception, the anti-
allodynic effect of morphine + SP600125 combination
treatment was no longer present (F3,18 = 1.48, p = 0.447
(day 21); 0.97, p = 0.428 (day 22); 1.28, p = 0.312 (day
23); 1.55, p = 0.237 (day 24); 1.92, p = 0.163 (day 25))
(Fig. 5c). Thus, SP600125 alone produced intrinsic anti-
nociceptive efficacy and when combined with morphine
it delays tolerance to the anti-allodynic effects of mor-
phine. This finding suggests that tolerance to effects of
SP600125 on JNK signaling may serve as the basis for
the eventual development of tolerance to morphine
when both are co-administered.Assessment of cold allodynia following administration
of SP600125, morphine, and their combination in
cisplatin-treated mice
Responsiveness to acetone was increased in the cisplatin-
treated group relative to the saline group (F1,28 = 6481.82,
p < 0.0001), consistent with development of cold allodynia
(Fig. 6a). Cold allodynia was present in cisplatin-treated
mice throughout the duration of this study from day 8 to
Fig. 5 (See legend on next page.)
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Fig. 5 Treatment with SP600125 delays tolerance to the anti-allodynic effect of morphine on responsiveness to mechanical stimulation. Cisplatin
produces time-dependent sensitization to mechanical stimulation. The time course for the development of mechanical allodynia (a) in cisplatin-
treated relative to saline treated-mice. Baseline paw withdrawal thresholds (b) prior to treatment with vehicle, SP600125 (3 mg/kg i.p.), morphine
(6 mg/kg i.p.) or their combination. Paw withdrawal thresholds 30 min after treatment (c) with these drug combinations. Data are expressed as
mean ± S.E.M. (n = 5–6 per group). *p < 0.013 vs. vehicle or saline group (ANOVA, Bonferroni post hoc); + p < 0.006 vs. morphine or morphine with
SP600125 groups (ANOVA, Bonferroni post hoc); #p < 0.01 vs. SP600125 given alone (ANOVA, Bonferroni post hoc); x p < 0.001 vs. morphine with
SP600125 (ANOVA, Bonferroni post hoc)
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line responsiveness to cold did not differ in any group
(F3,18 = 1.64, p = 0.215) at any time point (F54,324 = 0.95,
p = 0.569) (Fig. 6b). Response time to cold stimulation
was similar in groups receiving vehicle, morphine (6 mg/
kg), SP600125 (3 mg/kg, or morphine (6 mg/kg) com-
bined with SP600125 (3 mg/kg) from day 8 (F3,18 = 1.75,
p = 0.192) to day 25 (F3,18 = 1.45, p = 0.263) (Fig. 6b).
Morphine (6 mg/kg; given from day 11 to day 25),
SP600125 (3 mg/kg; given from day 8 to day 25) and
their combination (3 mg/kg SP600125 from day 8 to day
25 + 6 mg/kg morphine from day 11 to day 25) were
chronically administered (i.p.) and tested for their anti-
allodynic effect on cisplatin-induced neuropathic pain
(Fig. 6c). Morphine (6 mg/kg), SP600125 (3 mg/kg), and
their combination all suppressed cisplatin-induced cold
allodynia relative to vehicle (F3,18 = 2704.06, p < 0.0001)
(Fig. 6c). Morphine (6 mg/kg), SP600125 (3 mg/kg), and
their combination also produced time-dependent (F54,324 =
201.45, p < 0.0001) attenuation of cold allodynia relative to
pre-injection baselines. The attenuation of cold allodynia
induced by SP600125 alone or the combination of mor-
phine and SP600125 was observed relative to the vehicle
group from day 8 (F3,18 = 212.64, p < 0.0001) to day 22
(F3,18 = 15.87, p < 0.0001) (Fig. 6c).
Morphine treatment alone (6 mg/kg) reversed cisplatin-
induced cold allodynia relative to vehicle from day 11 (p <
0.0001) to day 14 (p < 0.0001) (Fig. 5c). Additionally, mor-
phine administered alone lowered time responses to cold
stimulation to a greater extent than SP600125 adminis-
tered alone from day 11 (p < 0.0001) to day 13 (p < 0.004).
However, morphine’s anti-allodynic effect dissipated over
time, consistent with development of tolerance to mor-
phine. Consequently, morphine no longer produced anti-
nociception starting on its fifth consecutive day of
administration (day 15). Indeed, from day 15 to day 25,
morphine (6 mg/kg) no longer produced anti-allodynic ef-
fect relative to vehicle (p > 0.164) (Fig. 6c).
Interestingly, SP600125 (3 mg/kg) alone alleviated
cisplatin-induced cold allodynia relative to vehicle from
day 8 (p < 0.0001) to day 22 (p < 0.001). On day 14,
SP600125 given alone showed lower (p < 0.0001) time
responses to cold stimulation than morphine given alone
(Fig. 6c).Morphine (6 mg/kg) combined with SP600125 (3 mg/
kg) suppressed cisplatin-induced cold allodynia in com-
parison to the vehicle group from day 8 (p < 0.0001) to
day 22 (p < 0.001). Morphine combined with SP600125
lowered time responses to cold stimulation with a simi-
lar magnitude as morphine alone on day 11 (p = 1.000)
and on day 12 (p = 1.000). The anti-allodynic effect of
morphine combined with SP600125 was greater than the
anti-allodynia seen with administration of morphine or
SP600125 given alone from day 13 (p < 0.0001 for each
comparison) to day 21 (p < 0.0001 for each comparison).
On day 22, mice receiving the combination of morphine
with SP600125 showed a similar response to cold stimu-
lation (p = 1.000) as did mice receiving SP600125 alone,
and both groups had significantly lowered responses to
cold stimulation relative to vehicle/morphine groups (p <
0.001). Thus, anti-allodynic efficacy of the combination
treatment of SP600125 with morphine was apparent dur-
ing the interval when SP600125 produced antinociception
and tolerance to morphine anti-allodynic efficacy was de-
veloping. From day 23 to day 25, the anti-allodynic effect
was no longer observed in any treatment group (F3,18 =
1.10, p = 0.376 (day 23); 0.62, p = 0.610 (day 24); 2.32, p =
0.110 (day 25)), Fig. 6c).
Discussion
In this study, morphine antinociception was measured
in multiple assays using the formalin, tail-flick, and hot-
plate tests, and also by measuring suppression of mech-
anical and cold allodynia in a chemotherapy-induced
neuropathic pain model. We found that SP600125 pro-
duces dose-dependent antinociceptive effects in the for-
malin test. Our results in the formalin test demonstrate
that co-administration of SP600125 (3 and 10 mg/kg)
and morphine (6 mg/kg) produces a sub-additive antino-
ciceptive effect compared to treatment with either mor-
phine (6 mg/kg) or SP600125 (3 mg/kg) alone. We also
found that pre-treatment with SP600125 (3 and 10 mg/
kg) slows the development of tolerance to the antinoci-
ceptive effects of morphine. During a ten day treatment
course, SP600125 pre-treatment prevented the develop-
ment of complete tolerance to morphine-induced tail-
flick antinociception (five day delay before any evidence
of tolerance was detected) and a one day delay in
Fig. 6 (See legend on next page.)
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Fig. 6 Treatment with SP600125 delays tolerance to the anti-allodynic effect of morphine on responsiveness to cold stimulation. Cisplatin
produces time-dependent sensitization to cold stimulation. The time course for the development of cold allodynia (a) in cisplatin-treated relative
to saline treated-mice. Baseline paw latencies in response to cold stimulation (b) prior to treatment with vehicle, SP600125 (3 mg/kg i.p.),
morphine (6 mg/kg i.p.) or their combination. Paw latencies in response to cold stimulation 30 min after treatment (c) with these drug combinations.
Data are expressed as mean ± S.E.M. (n = 5–6 per group). *p < 0.001 vs. vehicle or saline group group (ANOVA, Bonferroni post hoc); + p < 0.004 vs.
morphine or morphine with SP600125 groups (ANOVA, Bonferroni post hoc); #p < 0.0001 vs. SP600125 given alone (ANOVA, Bonferroni post hoc); x
p < 0.0001 vs. morphine with SP600125 (ANOVA, Bonferroni post hoc); ^p < 0.0001 vs. SP600125 alone or morphine with SP600125 groups (ANOVA,
Bonferroni post hoc); t p < 0.001 vs. vehicle or morphine (ANOVA, Bonferroni post hoc)
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Consistent with previous work, we found that tolerance
for the antinociceptive effect of fentanyl was not affected
by SP600125, providing additional evidence of function-
ally selective mechanisms of opioid tolerance. Finally,
SP600125 (3 mg/kg) alone attenuated mechanical and
cold allodynia in cisplatin-treated mice. Strikingly,
SP600125 (3 mg/kg) pre-treatment prolonged the anti-
allodynic effect of morphine by several days (5 and 7 days
for mechanical and cold, respectively) depending on the
modality. These results demonstrate that JNK signaling
plays a crucial role in directly mediating antinociception
but is also involved in chronic tolerance to morphine
antinociception in acute, inflammatory and neuropathic
pain assays.
A noteworthy observation from our studies is that in-
hibition of JNK through systemic SP600125 (i.p.) admin-
istration produces antinociception in an inflammatory
pain model (formalin test) in a dose-dependent manner.
Indeed, our study demonstrates that 3 mg/kg of SP600125
produced the greatest antinociceptive effect compared to
other doses (0.1, 1 and 10 mg/kg i.p.) in the formalin test.
Likewise, it also seems that 3 mg/kg SP600125 is the bet-
ter dose compared to 10 mg/kg for preventing tolerance
to morphine in the hotplate and tail-flick tests. However,
further studies outside the scope of the current manu-
script would be necessary to confirm conclusively whether
the shape of the dose–response curve for the effect of
SP600125 on morphine tolerance and antinociception are
bell or sigmoidally shaped. The alleviation of pain by
SP600125 in our inflammatory pain model corroborates a
previous study reporting that local peripheral
administration of SP600125 produces antinociceptive ef-
fects in melittin (principal toxic peptide from whole bee
venom)-induced nociception [23]. One study found that
formalin increased expression of phosphorylated MAPKs
(mitogen-activated protein kinases) in the spinal cord in-
cluding phospho-p38, phospho-ERK and phospho-JNK
[24]. While yet another study demonstrates the beneficial
effect of SP600125 on pain (weight bearing) in an arthritis
model [25]. The attenuation of the nociceptive response
of SP600125 following intrathecal administration in the
formalin test has been investigated [26]. However, our
study is the first to demonstrate that systemicadministration of JNK inhibitor (SP600125 at 3 mg/kg)
combined with morphine (6 mg/kg) produces a sub-
additive antinociceptive effect in the formalin test. One
possible explanation for this sub-additive antinociceptive
effect when morphine and SP600125 are combined is that
SP600125 drives enhanced antinociception by decreasing
the activation of peripheral MAPKS such as phospho-JNK
[24].
Our study also demonstrates that two doses (3 or
10 mg/kg) of JNK inhibitor (SP600125) attenuated chronic
tolerance to the antinociceptive effects of morphine in the
tail-flick and hotplate tests. This finding corroborates pre-
vious studies demonstrating that JNK signaling mediates
chronic tolerance for the antinociceptive effects of mor-
phine in the tail-flick test [15, 21]. Interestingly, SP600125
(3 mg/kg) pre-treatment prolonged the maximal antinoci-
ceptive effect of morphine by several days (3 and 8 days
for hotplate and tail-flick tests, respectively) depending on
the assay. Previous work using the hotplate assay revealed
a learning phenomenon that causes basal response laten-
cies to decrease during repeated testing [27]. Since our ex-
periment involved repeated daily testing of mice using the
hotplate, it is possible that the diminishment in hotplate
response observed could be due to the mouse learning to
exhibit certain behaviors in order to be removed from the
hotplate apparatus [28, 29]. Thus, we would likely observe
a more pronounced effect of SP600125 on hotplate anti-
nociception if daily experiments were obtained from sep-
arate cohorts of hotplate-naïve, morphine-treated mice.
In acute pain tests, chronic tolerance to morphine, a
modestly efficacious and weakly internalizing MOR
agonist, is mediated primarily by JNK while tolerance to
the more efficacious and strongly internalizing opioid,
fentanyl is not [4, 15, 21] (Fig. 7). Thus, antinociceptive
tolerance for strongly internalizing (e.g., fentanyl) MOR
ligands may be mediated by a ‘classical’ GRK/βarrestin
mechanism while tolerance for weakly internalizing li-
gands (e.g., morphine) is likely to be mediated by JNK
signaling mechanisms, potentially in a cell-type specific
manner [4, 15, 21] (Fig. 7).
One surprising result from this study was the finding
that JNK inhibition attenuated hypothermic tolerance to
fentanyl. Based on previous work examining the role of
JNK in acute tolerance for the analgesic effects of
Fig. 7 Schematic representation of different hypotheses/mechanisms involved in the development of tolerance to the antinociceptive effect of
fentanyl and morphine. Down-regulation and desensitization of MOR represent two possible biochemical processes that could underlie JNK-
mediated morphine tolerance in vivo. The findings of our study and others suggests that tolerance for the antinociceptive effects of morphine is
mediated by JNK signaling, possibly through desensitization of MOR, defined for this study as the functional uncoupling of the receptor from its
G protein signaling components. In contrast, inhibition of JNK does not alter tolerance for the antinociceptive effects of fentanyl. Tolerance for
the antinociceptive effects of fentanyl appears to be mediated by a classic mechanism involving GRK phosphorylation of MOR followed by
βarrestin2 recruitment
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tolerance for any of the physiological effects of fentanyl
[20]. Our results that SP600125 does appear to affect
tolerance for the hypothermic effect of morphine and
fentanyl raises the possibility that divergent cell-type
specific tolerance mechanisms might exist for the anti-
nociceptive compared to thermoregulatory effects of fen-
tanyl. For example, JNK-mediated tolerance might occur
in thermoregulatory neurons of the preoptic anterior
hypothalamus (POAH) that express MOR and mediate
the hypothermic effects of morphine and fentanyl [30].
This study is the first to demonstrate that systemic
administration of JNK inhibitor (SP600125 at 3 mg/kg) sup-
presses mechanical and cold allodynia in a chemotherapy-
induced neuropathic pain model using cisplatin. Our
finding corroborates previous research that demon-
strated intrathecal administration of SP600125 produces
anti-allodynic effects in a spinal nerve ligation model of
neuropathy [31]. Interestingly, the anti-allodynic effects
of morphine are greater than those of SP600125 admin-
istered alone and diminishment of the morphine-specific
anti-allodynic component is delayed by pre-treatment
with SP600125. However, we found that treatment with
SP600125 alone does not have significant effects on ei-
ther tail-flick or hotplate antinociception, possibly dueto signaling changes induced by toxic neuropathy or
differences in the neuronal cell-types and/or signaling
pathways associated with the different pain states or
testing paradigms. JNK inhibition alone appears to be
ineffective at alleviating acute (tail-flick and hotplate)
pain, although we did observe antinociception in inflam-
matory and chemotherapy-induced neuropathic pain
models. It has been demonstrated previously that many
antinociceptive compounds are more effective in chronic
pain [32] relative to acute pain models.
We also find that pre-treatment with SP600125 signifi-
cantly delays tolerance to the anti-allodynic effects of
morphine for both mechanical and cold allodynia in
chemotherapy-induced peripheral neuropathy in cisplatin-
treated mice. Our work supports previous studies showing
that JNK signaling is essential for tolerance to morphine
in sciatic nerve injury-induced neuropathic pain [22].
However, we extend the role of JNK-mediated morphine tol-
erance to a highly clinically relevant model of chemotherapy-
induced neuropathy by demonstrating that JNK mediates
morphine tolerance in a chemotherapy-induced pain model.
The precise mechanisms through which JNK mediates
tolerance to morphine are still being elucidated. However,
down-regulation and/or desensitization of MOR represent
two possible biochemical processes that could underlie
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shown that treatment with SP600125 prevents the reduc-
tion of D-Ala2-Met5-Glyol-enkephalin (DAMGO)-stimu-
lated [35S] sGTPγS binding in spinal cord homogenates
that is caused by repeated treatment with morphine, but
doesn’t affect down regulation caused by repeated treat-
ment with fentanyl [20]. Subsequent work has shown that
JNK facilitates desensitization of voltage-gated calcium
channel inhibition in DRG neurons [33]. These findings
indicate that desensitization of MOR, defined for this
study as the functional uncoupling of the receptor from
its G protein signaling components, is at least partially re-
sponsible for JNK-mediated tolerance for the antinocicep-
tive effects of morphine (Fig. 7). Despite this evidence, it is
important to note that tolerance to MOR agonists can be
influenced by a number of other pharmacodynamic pro-
cesses including, but not limited to, NMDA receptor
modulation [15], nitric oxide signaling pathways (which
can include JNK) [16], and protein kinase C activity [17].
Conclusions
The present study provides direct evidence that chronic
tolerance to morphine is mediated at least partially by a
JNK mechanism in acute, inflammatory and neuropathic
pain states. Indeed, we found that inhibition of JNK,
using SP600125, produced a dose-dependent antinoci-
ceptive effect in the formalin test. Moreover, combin-
ation treatment with SP600125 and morphine produced
a sub-additive antinociceptive effect. In the assessment
of JNK inhibition on acute pain, we observed that
SP600125 attenuates chronic tolerance to the antinoci-
ceptive effects of morphine, but not fentanyl in the tail-
flick and hotplate tests. This supports previous reports
that chronic tolerance for opioids occurs in an agonist
specific manner suggesting that functional selectivity ex-
tends to GPCR desensitization mechanisms and tolerance
pathways. SP600125 also attenuated cisplatin-induced me-
chanical and cold allodynia in a chemotherapy-induced
toxic neuropathy model. Strikingly, SP600125 pre-treatment
prolonged the anti-allodynic effect of morphine by several
days (5 and 7 days for mechanical and cold, respectively).
These results demonstrate that JNK signaling plays a crucial
role in mediating antinociception and chronic tolerance to




Experiments were performed using wild-type C57Bl6/J
mice obtained from Jackson Laboratories (Bar Harbor,
Maine). Mice used in these experiments were housed
under a 12:12 h light–dark cycle (lights on 07:00, lights
off 19:00) and provided with standard mouse chow ad
libitum. All animal care and experimental proceduresused in this study were approved by the Institutional
Animal Care and Use Committee of the Penn State Univer-
sity College of Medicine or Indiana University Bloomington
and conform to the Guidelines of the National Institutes
of Health on the Care and Use of Animals.
Drugs
Morphine sulfate was purchased from Sigma Aldrich (St.
Louis, MO) and was also obtained from National Insti-
tute on Drug Abuse Drug Supply (Bethesda, MD). Fen-
tanyl was obtained from the National Institute on Drug
Abuse Drug Supply (Bethesda, MD). SP600125 was ob-
tained from Sigma-Aldrich (St. Louis, MO) [19]. Cis-
platin and 4 % sodium bicarbonate (NaHCO3 dissolved
in 0.9 % NaCl) were purchased from Tocris (Ellisville,
MO). Morphine, fentanyl, cisplatin and sodium bicar-
bonate were dissolved in normal saline (0.9 % NaCl in
water) for in vivo administration. A 25 mg/ml stock so-
lution of SP600125 was prepared in 100 % DMSO and
was subsequently diluted in vehicle containing 0.9 % sa-
line, 5 % Kolliphor EL, 5 % ethanol (18:1:1 vehicle) for
in vivo administration. The total amount of DMSO con-
tained in all SP600125 and corresponding vehicle injec-
tions was 4 % (v/v). Doses of morphine and SP600125
were chosen that were previously shown to be effica-
cious in tail-flick, hotplate, and chemotherapy-induced
neuropathic pain models [19–22, 34]. SP600125 was
stored at −20 °C whereas morphine, fentanyl, cisplatin
and sodium bicarbonate were stored at room temperature.
The drugs or vehicle were prepared fresh on the day of
the experiment and administered intraperitoneally (i.p.;
SP600125) or subcutaneously (s.c.; morphine or fentanyl)
in a single volume of 10 ml/kg of body weight.
Procedures
First, the antinociceptive effect of different doses of
SP600125 (0.1, 1, 3 and 10 mg/kg i.p.) were assessed
relative to vehicle using the formalin test (2.5 %). Sec-
ond, the antinociceptive effect of SP600125 in combin-
ation with morphine was determined in another group
of mice to evaluate the presence of a greater antinoci-
ceptive effect when these drugs were given together.
Third, tail-flick and hotplate antinociception as well as
hypothermia were measured in different mice receiving ei-
ther sub-cutaneous (s.c.) injections of morphine (10 mg/
kg × 10 days) or fentanyl (0.3 mg/kg × 10 days) [20]. One
hour prior to administration of morphine or fentanyl,
mice were pretreated with intraperitoneal (i.p.) injections
of either vehicle, 3 mg/kg SP600125, or 10 mg/kg
SP600125. Daily measurements of body temperature and
tail-flick and hotplate responses were recorded before ad-
ministration of any vehicle or drug (pre-test) and one hour
after treatment with morphine or fentanyl. Tolerance to
morphine or fentanyl was examined in mice treated
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tanyl alone or in combination with SP600125. Two weeks
after cessation of drug treatment, recovery from tolerance
to the antinociceptive effect of morphine was assessed in
the tail-flick and hotplate tests following pre-treatment
with vehicle, SP600125 (3 mg/kg), or SP600125 (10 mg/
kg) given 60 min prior to a challenge dose of morphine or
fentanyl.
Fourth, a separate cohort of mice was used to measure
mechanical and cold allodynia in cisplatin-treated mice
receiving either vehicle only (day 8–25), morphine (6 mg/
kg, day 11–25) only, SP600125 (3 mg/kg, day 8–25) only,
or SP600125 (3 mg/kg, day 8–25) pre-treatment 30 min
prior to subsequent treatment with vehicle or morphine
(6 mg/kg, day 11–25).
Formalin test
The formalin test is a well-established model of persist-
ent pain characterized by a transient, biphasic pattern of
pain behaviour. The early phase is characterized by acute
activation of C and Aδ fibers. The late phase involves an
inflammatory reaction in peripheral tissue [35], the devel-
opment of central nervous system sensitization [36, 37],
and additionally involves activation of primary afferent
nociceptors [38]. Mice were acclimatized to the testing en-
vironment (clear Plexiglass box 10 x 10 x 10 cm) during
15 min or until cessation of exploratory behaviour. Mice
were injected intraperitoneally (i.p.) with either SP600125
(0.1, 1, 3, 10 mg/kg), morphine (6 mg/kg) or their combin-
ation (SP600125 3 mg/kg +morphine 6 mg/kg). Following
each injection, the mice were immediately placed back in
the observation chamber. Nociceptive behaviour was ob-
served with the help of a mirror angled at 45° below the
observation chamber. Observation of the animal’s behav-
iour was performed in consecutive 5-min periods for
60 min following administration of 2.5 % formalin (10 μl).
In each 5-min bin, the total time the animal spent in three
different behavioural categories was recorded: (0) the
injected paw has little or no weight placed on it; (1) the
injected paw is raised; (2) the injected paw is licked,
shaken or bitten. Nociceptive behaviour was quantified
using the composite pain score-weighted scores technique
(CPS-WST0,1,2) [39], where each pain behaviour is weighted
by the amount of time spent in each category (0,1,2). The
area under the curve (AUC), which corresponds to CPS-
WST0,1,2 x time (min) was calculated for the acute phase
(0–15 min; Phase 1) and the inflammatory phase (15–
60 min; Phase 2) using the trapezoidal rule.
Assessment of tail-flick and hotplate antinociception
Tail-flick antinociception was measured using a Columbus
Instruments TF-1 tail-flick analgesia meter (Columbus,
OH). The radiant heat source on the apparatus was cali-
brated to elicit a tail-flick latency of 3–4 s in untreatedwild-type control mice. A 10 s cutoff was used for all tail-
flick tests to avoid tissue damage to the tail. Tail-flick re-
sponse latencies were measured in a single cohort of
animals daily for ten consecutive days and also on day 24,
before administration of SP600125 and morphine or fen-
tanyl (pre-test) and 60 min after treatment with fentanyl
or morphine (post-test).
Hotplate antinociception testing was measured using a
hotplate testing meter from Columbus Instruments set to
55 °C (Columbus, OH). A 30 s cutoff was used to avoid
paw tissue damage. The hotplate response latencies were
measured in a single cohort of animals for ten consecutive
days and also on day 24, both before administration of any
drugs and also 60 min after treatment with morphine or
fentanyl. The hotplate and tail-flick analgesic responses
were calculated as the percentage the maximal possible ef-
fect (%MPE) with %MPE = (post-drug latency – pre-drug
latency)/(10 – pre-drug latency) × 100 for tail flick anal-
gesia and %MPE = (post-drug latency – pre-drug latency)/
(30- pre-drug latency) for hotplate antinociception.
Measurement of body temperature
Body temperature was measured using a mouse rectal
thermometer (Physitemp, Clifton, NJ) to assess possible
drug-induced hypothermia. Body temperature was mea-
sured in a single cohort of animals daily for ten consecu-
tive days and also on day 24 before drug administration
and also at 60, 120, 180, and 240 min after morphine or
fentanyl injection.
Development of neuropathy
Cisplatin was administered intraperitoneally (i.p.) once a
week at a dose of 5 mg/kg for 25 days (cumulative dose:
20 mg/kg i.p.) [40]. Cisplatin was diluted in normal sa-
line (0.9 % NaCl) and delivered in a volume of 10 ml/kg
body weight. Control groups were injected with an
equivalent volume of saline (i.p. injection) in lieu of cis-
platin [34, 41]. Before each cisplatin/saline injection, a
4 % solution of sodium bicarbonate (NaHCO3 dissolved
in 0.9 % NaCl) [41] was administered subcutaneously
(1 ml). Injections were always performed after comple-
tion of mechanical and cold withdrawal testing.
Assessment of mechanical allodynia
Mechanical withdrawal thresholds were assessed using a
digital Electrovonfrey Anesthesiometer (IITC Life Sci-
ences, Woodland Hills, CA) equipped with a semi-flexible
tip as described previously [34, 41, 42]. Mice were placed
in individual plastic cages on an elevated wire mesh plat-
form, and were allowed to habituate to the testing appar-
atus for at least 30 min until exploratory behavior was no
longer observed. Force was applied to the midplantar re-
gion of each hind paw in each study by the same experi-
menter. Stable baseline responses were obtained prior to
Marcus et al. Molecular Pain  (2015) 11:34 Page 14 of 15experimental testing. Mechanical stimulation was termi-
nated upon paw withdrawal; consequently, there was no
upper threshold limit set for termination of a testing trial.
Paw withdrawal thresholds were assessed in duplicate for
each paw. Mechanical withdrawal thresholds were mea-
sured over 25 days. Testing took place on day 0 and daily
from day 8 to 25 for all animals.Assessment of cold allodynia
Cold allodynia was measured by applying a drop of acet-
one to the plantar surface of the hind paw as previously
described [34, 42]. Mice were placed in individual plastic
cages on an elevated platform and were habituated for at
least 30 min until exploratory behaviors ceased. Acetone
was loaded into a 1 mL syringe with no needle. Air bub-
bles were cleared from the syringe prior to acetone ap-
plication. One drop of acetone (approximately 20 μl)
was applied through the mesh platform onto the plantar
surface of the hind paw. Care was taken to gently apply
the bubble of acetone to the skin on the paw without in-
ducing mechanical stimulation through contact of the
syringe barrel with the paw. Time spent attending to the
acetone-stimulated paw was measured over a 60 s obser-
vation period after acetone application was recorded.
Paw withdrawal was sometimes associated with a sec-
ondary response with the animal, such as rapid flicking
of the paw, chattering, biting, and/or licking of the paw.
Testing order alternated between paws (i.e., right and
left) until five measurements were taken for each paw.
An interstimulation interval of approximately 5 min was
allowed between testing of right and left paws. Cold allo-
dynia testing took place on day 0 and daily from day 8
to 25 for all animals.Data analysis and statistics
All experiments were conducted in a blinded manner.
Animals were randomly assigned to experimental condi-
tions. Pain behaviour for each treatment group was
expressed as mean ± SEM. Paw withdrawal thresholds
(mechanical) and latencies (cold) were calculated for
each paw and averaged. Data were analyzed using analysis
of variance (ANOVA) for repeated measures or one-way
ANOVA as appropriate. The Greenhouse-Geisser correc-
tion was applied to all repeated factors; degrees of freedom
reported for significant interactions are the uncorrected
values. The source of significant interactions was further
evaluated by performing one-way ANOVAs at each indi-
vidual time point, followed by Bonferroni post hoc tests.
The different components of the total variation were set-
tled a priori using multiple regression analysis [43]. Ana-
lyses were performed using SPSS statistical software
(version 21.0; SPSS Incorporated, Chicago, IL, USA). P <
0.05 was considered significant.Abbreviations
AC: Adenylyl cyclase; ANOVA: Analysis of variance; AUC: Area under the
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GRK: G Protein-coupled Receptor Kinase; JNK: c-Jun N-terminal kinase; α, β
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